Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Revenue (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Revenue for 13 consecutive years, with $303000.0 as the latest value for Q4 2025.

  • Quarterly Revenue rose 29.49% to $303000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $790000.0 through Dec 2025, up 18.8% year-over-year, with the annual reading at $486000.0 for FY2025, 54.32% down from the prior year.
  • Revenue hit $303000.0 in Q4 2025 for Vistagen Therapeutics, up from $258000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $893000.0 in Q3 2022 to a low of -$15000.0 in Q1 2025.
  • Historically, Revenue has averaged $273805.0 across 5 years, with a median of $251000.0 in 2025.
  • Biggest five-year swings in Revenue: soared 351.28% in 2023 and later plummeted 109.15% in 2025.
  • Year by year, Revenue stood at $358000.0 in 2021, then tumbled by 49.72% to $180000.0 in 2022, then skyrocketed by 128.33% to $411000.0 in 2023, then tumbled by 43.07% to $234000.0 in 2024, then grew by 29.49% to $303000.0 in 2025.
  • Business Quant data shows Revenue for VTGN at $303000.0 in Q4 2025, $258000.0 in Q3 2025, and $244000.0 in Q2 2025.